| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,183 |
12,902 |
$1.21M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,101 |
8,441 |
$565K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
3,213 |
3,107 |
$175K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
6,741 |
6,443 |
$91K |
| 36415 |
Collection of venous blood by venipuncture |
11,059 |
10,165 |
$57K |
| 99215 |
Prolong outpt/office vis |
425 |
391 |
$51K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
651 |
613 |
$47K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
948 |
393 |
$43K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
982 |
904 |
$43K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
462 |
459 |
$38K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
1,877 |
1,810 |
$36K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
338 |
331 |
$25K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
280 |
274 |
$22K |
| X5622 |
|
186 |
156 |
$16K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
650 |
612 |
$16K |
| 99223 |
Prolong inpt eval add15 m |
130 |
121 |
$15K |
| 90686 |
|
2,368 |
2,249 |
$13K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,273 |
1,239 |
$12K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,352 |
1,245 |
$11K |
| 92551 |
|
1,367 |
1,313 |
$10K |
| 99188 |
|
1,041 |
1,022 |
$8K |
| 0071A |
|
219 |
206 |
$8K |
| 91320 |
|
95 |
95 |
$8K |
| 90480 |
|
285 |
281 |
$8K |
| 0072A |
|
215 |
205 |
$8K |
| 99233 |
Prolong inpt eval add15 m |
116 |
52 |
$8K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
80 |
78 |
$7K |
| 80061 |
Lipid panel |
499 |
489 |
$7K |
| 96127 |
|
1,537 |
1,475 |
$6K |
| 0064A |
|
136 |
135 |
$5K |
| T1013 |
Sign language or oral interpretive services, per 15 minutes |
98 |
91 |
$5K |
| 85027 |
|
651 |
599 |
$4K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
153 |
152 |
$4K |
| 90677 |
|
14 |
14 |
$3K |
| 90662 |
|
57 |
56 |
$3K |
| 99460 |
|
60 |
58 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
74 |
73 |
$3K |
| 90656 |
|
382 |
381 |
$3K |
| 99173 |
|
1,538 |
1,486 |
$3K |
| 0001A |
|
75 |
74 |
$2K |
| 0004A |
|
60 |
60 |
$2K |
| 0002A |
|
62 |
61 |
$2K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
313 |
259 |
$2K |
| 0011A |
|
81 |
80 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
50 |
49 |
$2K |
| 90715 |
|
99 |
99 |
$2K |
| 90670 |
|
369 |
366 |
$2K |
| 80053 |
Comprehensive metabolic panel |
170 |
148 |
$2K |
| 0012A |
|
61 |
58 |
$2K |
| 86803 |
|
77 |
76 |
$1K |
| 81025 |
|
122 |
118 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12 |
12 |
$1K |
| 0054A |
|
25 |
25 |
$902.21 |
| 90682 |
|
30 |
25 |
$896.48 |
| 84443 |
Thyroid stimulating hormone (TSH) |
59 |
57 |
$878.88 |
| 90673 |
|
12 |
12 |
$841.64 |
| 99222 |
Initial hospital care, per day, moderate complexity |
12 |
12 |
$800.24 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
211 |
202 |
$608.72 |
| 90473 |
|
29 |
29 |
$551.72 |
| 90651 |
|
62 |
60 |
$503.74 |
| 99000 |
|
46 |
41 |
$485.94 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
13 |
12 |
$419.64 |
| 86780 |
|
30 |
30 |
$410.99 |
| 96161 |
|
267 |
264 |
$384.13 |
| 90474 |
|
42 |
42 |
$376.18 |
| G0008 |
Administration of influenza virus vaccine |
33 |
33 |
$344.31 |
| 87210 |
|
56 |
52 |
$338.22 |
| 82043 |
|
55 |
55 |
$316.36 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
223 |
212 |
$274.25 |
| 0031A |
|
16 |
15 |
$239.44 |
| 82728 |
|
13 |
12 |
$144.00 |
| 90734 |
|
88 |
84 |
$126.04 |
| 36416 |
|
39 |
39 |
$116.72 |
| 85018 |
|
47 |
47 |
$116.55 |
| 81001 |
|
25 |
25 |
$83.28 |
| 81003 |
|
40 |
40 |
$35.20 |
| 90633 |
|
110 |
107 |
$0.00 |
| 90710 |
|
13 |
13 |
$0.00 |
| 90698 |
|
222 |
221 |
$0.00 |
| 90744 |
|
64 |
64 |
$0.00 |
| 90680 |
|
74 |
74 |
$0.00 |
| 90696 |
|
13 |
13 |
$0.00 |